In a significant step towards corporate restructuring, the Mumbai Bench of the National Company Law Tribunal (NCLT) has approved the first-motion application for the proposed merger of Docon Technologies Private Limited with API Holdings Limited, the parent company of PharmEasy.
The approval marks an important milestone in API Holdings’ efforts to simplify its organizational structure and strengthen operational efficiency across its healthcare and technology businesses.
What Is the Proposed Merger?
Docon Technologies is a wholly owned subsidiary of API Holdings and operates in the healthcare technology space. The company is known for developing and licensing digital healthcare solutions, including electronic medical records (EMR), teleconsultation platforms, and diagnostic management software.
Under the proposed scheme of amalgamation, Docon Technologies will be merged into API Holdings. Since Docon is already a 100% owned subsidiary, no new shares will be issued as part of the transaction. Upon completion of the merger, Docon’s share capital will stand cancelled and the company will cease to exist as a separate legal entity.
The boards of both companies had approved the merger proposal on October 14, 2025, with April 1, 2025, designated as the appointed date for the scheme.
Why Is API Holdings Pursuing This Merger?
According to the merger proposal, the amalgamation is primarily aimed at streamlining the group’s corporate structure and improving operational efficiencies.
The key objectives include:
- Simplifying the organizational framework.
- Eliminating duplication of functions and processes.
- Consolidating assets and liabilities under a single entity.
- Reducing compliance and administrative expenses.
- Improving resource utilization and management efficiency.
As healthcare and health-tech companies continue to focus on profitability and operational optimization, such internal restructuring initiatives are becoming increasingly common across the sector.
Understanding the First-Motion Approval
The NCLT’s approval represents the first stage of the merger process under Sections 230 to 232 of the Companies Act, 2013.
A first-motion order is essentially a procedural approval that allows the merger proposal to move forward. It does not constitute final sanction of the scheme. Before the merger becomes effective, the companies must complete additional regulatory and legal requirements, including obtaining final approval through the second-motion process before the NCLT.
What Does This Mean for PharmEasy?
While the merger does not directly impact PharmEasy’s day-to-day operations, it reflects API Holdings’ broader strategy of consolidating its businesses and creating a leaner corporate structure.
Over the past few years, India’s digital healthcare sector has witnessed intense competition, funding challenges, and a stronger focus on operational efficiency. By integrating Docon Technologies directly into API Holdings, the company aims to better align its healthcare technology assets with its broader business objectives.
The move is expected to enhance administrative efficiency, reduce overhead costs, and enable more streamlined decision-making across the group.
The Road Ahead
With the first-motion approval now secured, the merger process will proceed through the next stages of regulatory and judicial review. Once all statutory requirements are fulfilled and the NCLT grants final approval, Docon Technologies will officially merge into API Holdings.
For API Holdings and PharmEasy, the transaction represents another step toward organizational consolidation and long-term operational efficiency as the company continues to navigate an evolving healthcare and technology landscape.
